Erik founded groupH back in 2005 in London with a big vision but starting as a one-man-band working together with a number of trusted and like-minded associates. He both enjoyed commercial analysis and decision making and also had a passion to create a unique working environment that enabled talented and self-driven people to happily go the extra-mile for their clients. This philosophy underpins groupH’s vision to this day.
Erik’s early career started in Big Pharma and Generics Marketing at Hoechst in South America. His Cranfield MBA led him to The Wilkerson Group, which was at that time the leading consultancy for Opportunity Assessment work. It is there, and later at Wood Mackenzie, that Erik deepened his understanding of the factors that drive the commercial success of early stage novel therapeutics. This understanding has been refined over the years to reflect the ever greater needs of doctors, payers and patients. He has worked across broad oncology and CV indications but also in rare diseases and for regenerative therapies requiring new market access models.
Whether it is knowing the right people for your project, discussing your asset in-depth with doctors or payers, analysing product pipelines or teaching a yoga class after work or on weekends, Erik is interested as much in the detail as in big picture. This insight helps to put early to mid stage products onto the right path. It also enables him to support his team and clients who are operating in an increasingly complex and interconnected world. Family life and playing hide & seek with his young daughter balances the daily stresses of work challenges.